METHYLDOPA AND HYDROCHLOROTHIAZIDE Drug Patent Profile
✉ Email this page to a colleague
When do Methyldopa And Hydrochlorothiazide patents expire, and when can generic versions of Methyldopa And Hydrochlorothiazide launch?
Methyldopa And Hydrochlorothiazide is a drug marketed by Chartwell Rx, Dava Pharms Inc, Ivax Sub Teva Pharms, Parke Davis, Purepac Pharm, Rising, Sandoz, Strides Pharma, Teva, and Watson Labs. and is included in forty-three NDAs.
The generic ingredient in METHYLDOPA AND HYDROCHLOROTHIAZIDE is hydrochlorothiazide; methyldopa. There are thirty-two drug master file entries for this compound. Additional details are available on the hydrochlorothiazide; methyldopa profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for METHYLDOPA AND HYDROCHLOROTHIAZIDE?
- What are the global sales for METHYLDOPA AND HYDROCHLOROTHIAZIDE?
- What is Average Wholesale Price for METHYLDOPA AND HYDROCHLOROTHIAZIDE?
Summary for METHYLDOPA AND HYDROCHLOROTHIAZIDE
US Patents: | 0 |
Applicants: | 10 |
NDAs: | 43 |
Raw Ingredient (Bulk) Api Vendors: | 2 |
DailyMed Link: | METHYLDOPA AND HYDROCHLOROTHIAZIDE at DailyMed |